European Heart Journal· 2014Q1
Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency
- 1,222citations
- Q1SCImago
- 2014year
Short summary
Intravenous ferric carboxymaltose (FCM) improved 6-minute walk test distance by 33m at 24 weeks (P=0.002) and 36m at 52 weeks (P<0.001) compared to placebo in iron-deficient heart failure patients.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Hematology
HematologyMedicine